Biogen Idec goes into buy mode
Hope they don't forget the people that got them where they are today, us Avonex users:
Over the next two years, Biogen Idec will spend a good part of its $1.5 billion cash reserve to fill its pipeline of drug candidates. Mullen said the buying binge will, in large part, determine the success of the $6.4 billion merger, which created the country's third-largest biotech company.
Read it here.